Maccura expands diagnostic offerings with new medical device registrations

Maccura Biotechnology Co., Ltd. and its wholly-owned subsidiary, Maccura Medical Electronics Co., Ltd., recently obtained three new medical device registration certificates from the Sichuan Provincial Drug Administration. These include a blood gas and biochemistry analyzer (Q 600), urine analysis test strips, and urine conductivity analysis quality control and calibration products. The registration certificates are valid from December 22, 2025, to December 21, 2030.

The Q 600 blood gas and biochemistry analyzer is the company's first blood gas platform product, broadening its coverage in medical laboratory projects and enriching its in-vitro diagnostic product combination. The urine analysis test strips are designed for use with urine analyzers to aid in the diagnosis of kidney, diabetes, and urinary tract infections. The new quality control and calibration products are intended to monitor the stability of laboratory detection systems.

These new registrations are expected to enhance Maccura's comprehensive service capabilities within hospital laboratory settings and boost its overall market competitiveness. The company noted that actual sales performance will depend on future market promotion and cannot currently predict their impact on future operating revenue.